180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Update

180 Life Sciences Corp. (NASDAQ:ATNF) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 78,700 shares, a growth of 7.4% from the September 30th total of 73,300 shares. Based on an average daily volume of 1,780,000 shares, the short-interest ratio is currently 0.0 days. Currently, 16.1% of the shares of the stock are short sold.

180 Life Sciences Stock Down 11.3 %

180 Life Sciences stock opened at $3.93 on Thursday. 180 Life Sciences has a 52-week low of $1.16 and a 52-week high of $17.75. The firm’s fifty day moving average is $2.38 and its 200 day moving average is $2.03.

180 Life Sciences (NASDAQ:ATNF) last announced its quarterly earnings results on Monday, August 12th. The company reported $0.01 EPS for the quarter.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.